Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
In vitro mechanistic study demonstrating that esomeprazole modulates a signaling pathway implicated in gastric cancer cell invasion; raises a question about therapeutic potential rather than answering one in a clinical or animal model.
A systematic review of 10 trials with qualitative synthesis only, reporting descriptive findings about survival disparities without meta-analytic effect sizes, confidence intervals, or quantified comparisons between HER2-low and HER2-positive cohorts.
Two uncontrolled case reports describing a newly recognized adverse effect of tisotumab vedotin, with cytological mechanistic insight but no comparative data or systematic incidence assessment.
A single-center retrospective tissue microarray study with exploratory aims, no control group, and hypothesis-generating findings that establish target expression prevalence but lack sufficient power or design to establish clinical utility or practice-changing guidance.
Real-world observational study confirming efficacy of dual HER2 blockade in neoadjuvant HER2-positive breast cancer, consistent with historical trial data but limited by small single-centre sample and descriptive design.
A narrative review synthesizing biological rationale, mechanisms, and current clinical evidence for bispecific antibodies across gastrointestinal cancers, offering expert perspective on therapeutic potential and future directions rather than reporting a primary clinical trial result.
A narrative review synthesizing randomized trial evidence and recent regulatory approvals to propose a risk-adapted treatment framework for HER2-positive early-stage breast cancer, not reporting original trial data.